Bhaven Sampat, PhD, is an economist by training, centrally interested in issues at the intersection of health policy and innovation policy. His current projects examine the political economy of the National Institutes of Health, the effects of patents on access to medicines in India, the interactions between patent laws and FDA regulation in the pharmaceutical industry, the determinants of patent quality in the U.S. patent system, and challenges to evidence--based medicine in contexts of rapid technological change. Dr.Sampat has also written extensively on the effects of university patenting and "entrepreneurship" on academic medicine, and is actively involved in policy debates related to these issues. From 2001 to 2003, Dr.Sampat was an Assistant Professor at the School of Public Policy at Georgia Tech, where he won the "Faculty Member of the Year" teaching award for academic years 2001-2 and 2002-3. From 2003-2005 he was a Robert Wood Johnson Foundation Scholar in Health Policy Research at the University of Michigan.
Research Associate, National Bureau of Economic Research
Affiliated Faculty, Columbia Law School
Affiliated Faculty, School of International and Public Affairs
Honors & Awards
Areas of Expertise
Select Global Activities
TRIPS Implementation and Secondary Pharmaceutical Patenting: An Empirical Analysis: This project analyzes developing country strategies to limit the issuance of secondary patents in pharmaceuticals. Secondary patents may extend periods of exclusivity, delay generic entry, and contribute to high drug prices and reduced access to medicines. Accordingly, several developing countries have adopted policies to restrict the grants of such patents; such measures are widely promoted by analysts and international organizations alike. However, little is known about which countries are adopting what sorts of measures, and to what effect. The project develops a typology of approaches toward secondary patenting, and maps countries according to the typology. Empirical analyses focus on five countries with specific measures to limit secondary patenting and two without. The research involves assembling novel datasets of pharmaceutical patents filed in the seven countries, coding each application as primary or secondary, and examining outcomes for each application in each country. The analysis will not only generate cross-national data on grant rates for different types of drug applications, but also improve understanding of the effectiveness of different approaches to secondary patents. Quantitative analyses are complemented with case studies to reveal the social and political factors conditioning how patent policies work in practice.
Bhaven N. Sampat, Kristen Buterbaugh, and Marcel Perl. 2013. “New Evidence on the Allocation of NIH Funds across Diseases” Milbank Quarterly, March: 163-185.
Bhaven N. Sampat and Tahir Amin. 2013. “How Do Public Health Safeguards in Indian Patent Law Affect Pharmaceutical Patenting in Practice?” Journal of Health Politics, Policy, and Law.
Amy Kapczynski, Chan Park, and Bhaven N. Sampat. 2012. “Hydrates and Solvates and Salts (oh my!): Secondary Patents in Pharmaceuticals” PloS ONE, 12 December.
Bhaven N. Sampat, Ken Shadlen, and Tahir Amin. 2012. “Challenges to India’s Pharmaceutical Patent Laws” Science 337(6093): 414-5.
C. Scott Hemphill and Bhaven N. Sampat. 2012. “Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals” Journal of Health Economics, 327-329.
Mark Lemley and Bhaven N. Sampat. 2012. “Examiner Characteristics and Patent Office Outcomes.” Review of Economics and Statistics.
Bhaven N. Sampat and Frank Lichtenberg. 2011. “What Are The Respective Roles Of The Public And Private Sectors In Pharmaceutical Innovation?” Health Affairs. 30(2): 332-339.
Bhaven N. Sampat. 2010. “When Do Patent Applicants Search for Prior Art?”Journal of Law and Economics. 53: 399-416.
Bhaven N. Sampat. 2010. “Lessons from Bayh-Dole.” Nature. 468: 755-756.
C. Scott Hemphill and Bhaven N. Sampat. 2013. “Drug Patents at the Supreme Court.” Science 339(6126): 1386-1387